Key facts
- Notable investors include Industrifonden.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ZalVac
- ·The full record, as it builds
Funding rounds
No funding rounds for ZalVac are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ZalVac
Developer of immunization vaccines designed for inducing robust immunity against various strains of bacteria. The company's platform uses bacterial membrane vesicle technology to generate antigen-presenting particles, supports the development of vaccine candidates targeting multiple strains, and enables immune response stimulation, enabling pharmaceutical companies and research institutions to develop vaccines with broader protection.
- Sector
- Healthcare
- HQ
- Solna, Sweden
- Founded
- 2020
- Employees
- 1
- Website
- zalvac.com/
- Ownership
- Privately Held (backing)
ZalVac doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ZalVac shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ZalVac in its N-PORT filings yet. We sweep new filings monthly.